InvestorsHub Logo
Followers 467
Posts 26918
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 107

Friday, 02/08/2013 10:47:16 AM

Friday, February 08, 2013 10:47:16 AM

Post# of 122
SciClone to Present at BIO CEO & Investor Conference on February 12th
Press Release: SciClone Pharmaceuticals, Inc. – Mon, Feb 4, 2013 4:00 PM EST

FOSTER CITY, CA--(Marketwire - Feb 4, 2013) - SciClone Pharmaceuticals, Inc. ( NASDAQ : SCLN ) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 2:00 pm ET at the Waldorf Astoria Hotel in New York City.
To access the live audio webcast of these presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com, under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live events.
In addition, Dr. Blobel will participate in a panel discussion at the conference titled "Small Companies Thinking Big -- China Tactical Strategies" at 3:30 pm on February 11th.
About SciClone
SciClone Pharmaceuticals is a US-based, China-focused specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 14 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.